163 related articles for article (PubMed ID: 26986197)
1. Preclinical evaluations of peptide-conjugate vaccines targeting the antigenic domain-2 of glycoprotein B of human cytomegalovirus.
Finnefrock AC; Freed DC; Tang A; Li F; He X; Wu C; Nahas D; Wang D; Fu TM
Hum Vaccin Immunother; 2016 Aug; 12(8):2106-2112. PubMed ID: 26986197
[TBL] [Abstract][Full Text] [Related]
2. Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.
Nelson CS; Jenks JA; Pardi N; Goodwin M; Roark H; Edwards W; McLellan JS; Pollara J; Weissman D; Permar SR
J Virol; 2020 Apr; 94(9):. PubMed ID: 32051265
[TBL] [Abstract][Full Text] [Related]
3. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.
Nelson CS; Huffman T; Jenks JA; Cisneros de la Rosa E; Xie G; Vandergrift N; Pass RF; Pollara J; Permar SR
Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6267-6272. PubMed ID: 29712861
[TBL] [Abstract][Full Text] [Related]
4. Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response.
Cui X; Cao Z; Wang S; Lee RB; Wang X; Murata H; Adler SP; McVoy MA; Snapper CM
Vaccine; 2018 Sep; 36(37):5580-5590. PubMed ID: 30082162
[TBL] [Abstract][Full Text] [Related]
5. Antibodies to the major linear neutralizing domains of cytomegalovirus glycoprotein B among natural seropositives and CMV subunit vaccine recipients.
Marshall GS; Li M; Stout GG; Louthan MV; Duliège AM; Burke RL; Hunt LA
Viral Immunol; 2000; 13(3):329-41. PubMed ID: 11016597
[TBL] [Abstract][Full Text] [Related]
6. Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality.
Swanson EC; Gillis P; Hernandez-Alvarado N; Fernández-Alarcón C; Schmit M; Zabeli JC; Wussow F; Diamond DJ; Schleiss MR
Vaccine; 2015 Jul; 33(32):4013-8. PubMed ID: 26079615
[TBL] [Abstract][Full Text] [Related]
7. Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity.
Kirchmeier M; Fluckiger AC; Soare C; Bozic J; Ontsouka B; Ahmed T; Diress A; Pereira L; Schödel F; Plotkin S; Dalba C; Klatzmann D; Anderson DE
Clin Vaccine Immunol; 2014 Feb; 21(2):174-80. PubMed ID: 24334684
[TBL] [Abstract][Full Text] [Related]
8. Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies.
Loomis RJ; Lilja AE; Monroe J; Balabanis KA; Brito LA; Palladino G; Franti M; Mandl CW; Barnett SW; Mason PW
Vaccine; 2013 Jan; 31(6):919-26. PubMed ID: 23246547
[TBL] [Abstract][Full Text] [Related]
9. A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells.
McVoy MA; Lee R; Saccoccio FM; Hartikka J; Smith LR; Mahajan R; Wang JB; Cui X; Adler SP
Vaccine; 2015 Dec; 33(51):7328-7336. PubMed ID: 26597035
[TBL] [Abstract][Full Text] [Related]
10. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies.
Pötzsch S; Spindler N; Wiegers AK; Fisch T; Rücker P; Sticht H; Grieb N; Baroti T; Weisel F; Stamminger T; Martin-Parras L; Mach M; Winkler TH
PLoS Pathog; 2011 Aug; 7(8):e1002172. PubMed ID: 21852946
[TBL] [Abstract][Full Text] [Related]
11. Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus.
Fu TM; Wang D; Freed DC; Tang A; Li F; He X; Cole S; Dubey S; Finnefrock AC; ter Meulen J; Shiver JW; Casimiro DR
Vaccine; 2012 Dec; 30(52):7469-74. PubMed ID: 23107592
[TBL] [Abstract][Full Text] [Related]
12. Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice.
Wen Y; Monroe J; Linton C; Archer J; Beard CW; Barnett SW; Palladino G; Mason PW; Carfi A; Lilja AE
Vaccine; 2014 Jun; 32(30):3796-804. PubMed ID: 24837507
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity evaluation of DNA vaccines that target guinea pig cytomegalovirus proteins glycoprotein B and UL83.
Schleiss MR; Bourne N; Jensen NJ; Bravo F; Bernstein DI
Viral Immunol; 2000; 13(2):155-67. PubMed ID: 10892996
[TBL] [Abstract][Full Text] [Related]
14. Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.
Schleiss MR; Berka U; Watson E; Aistleithner M; Kiefmann B; Mangeat B; Swanson EC; Gillis PA; Hernandez-Alvarado N; Fernández-Alarcón C; Zabeli JC; Pinschewer DD; Lilja AE; Schwendinger M; Guirakhoo F; Monath TP; Orlinger KK
Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27795301
[TBL] [Abstract][Full Text] [Related]
15. DNA vaccines expressing glycoprotein complex II antigens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus (HCMV) isolates.
Shen S; Wang S; Britt WJ; Lu S
Vaccine; 2007 Apr; 25(17):3319-27. PubMed ID: 17287056
[TBL] [Abstract][Full Text] [Related]
16. A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques.
Wussow F; Yue Y; Martinez J; Deere JD; Longmate J; Herrmann A; Barry PA; Diamond DJ
J Virol; 2013 Feb; 87(3):1322-32. PubMed ID: 23152525
[TBL] [Abstract][Full Text] [Related]
17. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults.
Bernstein DI; Schleiss MR; Berencsi K; Gonczol E; Dickey M; Khoury P; Cadoz M; Meric C; Zahradnik J; Duliege AM; Plotkin S
J Infect Dis; 2002 Mar; 185(5):686-90. PubMed ID: 11865427
[TBL] [Abstract][Full Text] [Related]
18. Immunization of Rabbits with Recombinant Human Cytomegalovirus Trimeric versus Monomeric gH/gL Protein Elicits Markedly Higher Titers of Antibody and Neutralization Activity.
Cui X; Cao Z; Wang S; Flora M; Adler SP; McVoy MA; Snapper CM
Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31261659
[TBL] [Abstract][Full Text] [Related]
19. Detection of cytomegalovirus infection during clinical trials of glycoprotein B vaccine.
Zhang C; Pass RF
Vaccine; 2004 Dec; 23(4):507-10. PubMed ID: 15530699
[TBL] [Abstract][Full Text] [Related]
20. Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees.
Nelson CS; Vera Cruz D; Su M; Xie G; Vandergrift N; Pass RF; Forman M; Diener-West M; Koelle K; Arav-Boger R; Permar SR
J Virol; 2019 Mar; 93(5):. PubMed ID: 30518646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
